Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.
Press releases published on July 17, 2025
Peptides For Muscle Growth: How Oral Legal Peptides by Crazy Bulk Set New Benchmark For Bodybuilding Supplements and Muscle Building Results
GlobeNewswire
·
July 17, 2025
New York City, NY, July 17, 2025 (GLOBE NEWSWIRE) -- Introduction: Why Peptides for Muscle Growth Are Dominating the 2025 Supplement Scene As the demand for clean, high-performance muscle-building solutions rises, oral legal peptides are taking the fitness …
Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care
GlobeNewswire
·
July 17, 2025
WHO WHAT WHEN WHY Nuwellis, Inc. Termination of the REVERSE-HF clinical trial July 17, 2025 To redirect resources toward outpatient markets where scalable impact is highest. MINNEAPOLIS, July 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. today announced …
Repligen to Report Second Quarter 2025 Financial Results
GlobeNewswire
·
July 17, 2025
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release before the market …
Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache
GlobeNewswire
·
July 17, 2025
DURHAM, N.C., July 17, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies (“Palantir”) to automate and streamline the …
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
GlobeNewswire
·
July 17, 2025
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet …
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
GlobeNewswire
·
July 17, 2025
FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces …
Breckenridge Distillery Launches Mock One: Bold, Premium Non-Alcoholic Alternatives to Whiskey, Tequila, Gin & Rum - Crafted for Everyone Who Loves a Great Drink
GlobeNewswire
·
July 17, 2025
BRECKENRIDGE, Colo., July 17, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is pleased to announce the launch of Mock One, a new line of non- …
Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board
GlobeNewswire
·
July 17, 2025
Current Board member John Duke to succeed Jim Green as President …
BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes
GlobeNewswire
·
July 17, 2025
POMPANO BEACH, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the …
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
GlobeNewswire
·
July 17, 2025
Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future milestones for givastomig due to Bridge Health by I-Mab …
Aveanna Announces Second Quarter 2025 Earnings Release Date and Conference Call
GlobeNewswire
·
July 17, 2025
ATLANTA, July 17, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its second quarter results before the market open on Thursday, August 7, 2025, to be followed by a …
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
GlobeNewswire
·
July 17, 2025
MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss …
Teleflex Announces Second Quarter 2025 Earnings Conference Call Information
GlobeNewswire
·
July 17, 2025
WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To …
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
GlobeNewswire
·
July 17, 2025
VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …
Immuron - FY25 global sales exceed projection, up 49% on prior year
GlobeNewswire
·
July 17, 2025
Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter AUD$1.5 million up 58% on prior year …
Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement
GlobeNewswire
·
July 17, 2025
ROCKVILLE, Md. and SUZHOU, China, July 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in …
EAACI-Führung blickt auf rekordverdächtigen Kongress 2025 zurück: Ein entscheidender Moment für Allergologie und Immunologie
GlobeNewswire
·
July 17, 2025
ZÜRICH, July 17, 2025 (GLOBE NEWSWIRE) -- Mit über 7.600 Teilnehmern hat der EAACI-Kongress 2025 nicht nur aufgrund seiner Größe Schlagzeilen gemacht, sondern auch aufgrund der eindringlichen Botschaft seiner Führungskräfte. Nun, einen Monat nach Abschluss …
EAACI Leadership Reflects on Record-Breaking Congress 2025: A Pivotal Moment for Allergy and Immunology
GlobeNewswire
·
July 17, 2025
ZURICH, July 17, 2025 (GLOBE NEWSWIRE) -- With over 7,600 delegates in attendance, EAACI Congress 2025 made headlines not just for its scale but for the powerful message delivered by its leadership. Now, one month after the Congress concluded in Glasgow, …
La dirección de la EAACI reflexiona sobre el Congreso 2025, que batió récords: momento crucial para la alergia y la inmunología
GlobeNewswire
·
July 17, 2025
ZÚRICH, July 17, 2025 (GLOBE NEWSWIRE) -- El Congreso EAACI 2025 contó con la asistencia de más de 7600 delegados y fue noticia no solo por su magnitud, sino por el poderoso mensaje que transmitieron sus dirigentes. Ahora, un mes después de la clausura del …
La direction de l’EAACI fait le point sur son remarquable congrès 2025 représentant un tournant décisif pour l’allergologie et l’immunologie
GlobeNewswire
·
July 17, 2025
ZURICH, 17 juill. 2025 (GLOBE NEWSWIRE) -- Le congrès 2025 de l’EAACI a fait couler beaucoup d’encre à l’appui de ses 7 600 participants et plus, de son envergure et du message fort porté par son comité directeur. Un mois après la clôture de l’événement …